Literature DB >> 17188766

Combined prognostic value of peak O(2) uptake and microvolt level T-wave alternans in patients with idiopathic dilated cardiomyopathy.

Massimo Baravelli1, Cecilia Fantoni, Silvia Rogiani, Stefania Farina, Claudio Anzà, Valeria Caltabiano, Teresio Forzani, Jorge A Salerno-Uriarte.   

Abstract

BACKGROUND: Despite the great improvement in clinical management of patients with idiopathic dilated cardiomyopathy (DCM), sudden cardiac death (SCD) and death due to worsening heart failure (HF) remain a challenging problem. The assessment of oxygen consumption (peakVO(2)) has been recognized as an independent marker of mortality. Nevertheless peakVO(2) is not helpful in the risk stratification of SCD. Given this limitation, the association with another non-invasive test able to predict SCD such as microvolt level T-wave alternans (MTWA) would be useful.
OBJECTIVES: To determine the combined predictive value of peakVO(2) and MTWA in patients with DCM.
METHODS: Seventy consecutive DCM patients were prospectively investigated. PeakVO(2) and MTWA were determined during bicycle exercise testing. Primary composite study end-point was defined as major cardiac events (MCE): total cardiac death or documented sustained VT/VF (including appropriate ICD shock). Secondary end-point was defined as arrhythmic events (AE): SCD or documented sustained VT/VF.
RESULTS: Thirty-nine patients (55%) had a peakVO(2)<10 ml/kg/min, while 40 patients (57%) showed an abnormal MTWA test. During an average follow-up of 19.2+/-10.7 months, 11 MCE of which 6 AE have been documented. Among patients with abnormal MTWA and peakVO(2)<10 ml/kg/min 8 MCE of which 5 AE occurred while among patients with normal MTWA and peakVO(2)> or =10 ml/kg/min no event occurred. From multivariate analysis, the combined prognostic value of MTWA and peakVO(2) achieved statistical significance for MCE (p=0.03, HR 0.28, 95% CI 0.12-0.95) and for AE (p=0.05, HR 0.39, 95% CI 0.18-0.99) while MTWA alone was a significant predictor of AE (p=0.04, HR 0.32, 95% CI 0.14-0.93).
CONCLUSIONS: Our results suggest that only the association of MTWA and peakVO(2), but not the two single tests, is a significant prognostic marker of both MCE and AE in DCM patients. However, MTWA alone confirms its predictive power as arrhythmic risk stratifier in this population.

Entities:  

Mesh:

Year:  2006        PMID: 17188766     DOI: 10.1016/j.ijcard.2006.10.026

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

Review 1.  Predictive value of microvolt T-wave alternans for cardiac death or ventricular tachyarrhythmic events in ischemic and nonischemic cardiomyopathy patients: a meta-analysis.

Authors:  Leonardo Calò; Tiziana De Santo; Francesca Nuccio; Luigi Sciarra; Lucia De Luca; Lorenza Mangoni di S Stefano; Enrico Piroli; Lorenzo Zuccaro; Marco Rebecchi; Ermenegildo de Ruvo; Ernesto Lioy
Journal:  Ann Noninvasive Electrocardiol       Date:  2011-10       Impact factor: 1.468

Review 2.  T-wave alternans: reviewing the clinical performance, understanding limitations, characterizing methodologies.

Authors:  Euler de Vilhena Garcia
Journal:  Ann Noninvasive Electrocardiol       Date:  2008-10       Impact factor: 1.468

Review 3.  Non-invasive evaluation of arrhythmic risk in dilated cardiomyopathy: From imaging to electrocardiographic measures.

Authors:  Massimo Iacoviello; Francesco Monitillo
Journal:  World J Cardiol       Date:  2014-07-26

4.  Microvolt T-wave alternans, peak oxygen consumption, and outcome in patients with severely impaired left ventricular systolic function.

Authors:  Eiran Z Gorodeski; Daniel J Cantillon; Sachin S Goel; Elizabeth S Kaufman; David O Martin; Eileen M Hsich; Eugene H Blackstone; Michael S Lauer
Journal:  J Heart Lung Transplant       Date:  2009-05-13       Impact factor: 10.247

5.  Epidemiological and Outcomes Research in Children with Pediatric Cardiomyopathy: Discussions from the International Workshop on Primary and Idiopathic Cardiomyopathies in Children.

Authors:  Steven E Lipshultz; James D Wilkinson
Journal:  Prog Pediatr Cardiol       Date:  2008-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.